title: Treating infertility. Controlled ovarian hyperstimulation using human menopausal gonadotropin in combination with intrauterine insemination.
abstract: OBJECTIVE
  To determine the effectiveness of human menopausal gonadotropin (hMG) with intrauterine insemination (IUI) for the treatment of various causes of infertility and to identify prognostic factors for the success of this treatment.
  
  
  METHODS
  Retrospective chart analysis.
  
  
  RESULTS
  Of the 271 cycles initiated, 247 were completed in 104 couples, and analysis of these cycles showed that the overall cycle fecundity rate was 10% and the pregnancy rate 22%. The miscarriage rate was 8% and the ectopic pregnancy rate 4%. The multiple pregnancy rate was 29%. For the various causes of infertility, we found that the cycle fecundity rate was 7% for male factor, 11% for oligoovulation, 8% for tubal/pelvic factor, 13% for minimal endometriosis, 18% for mild endometriosis, 17% for moderate endometriosis, 3% for women aged > or = 40 years, 75% for myoma, and 7% for idiopathic infertility. We also found that one IUI timed at 36-48 hours was as effective as two IUIs timed at 18-24 and 36-48 hours after human chorionic gonadotropin (hCG) administration. Poor prognostic factors that were elicited from this study were: (1) failure of pregnancy in three cycles of treatment, (2) female age > or = 40 years, (3) requirement of > 300 IU of hMG daily, and (4) presence of more than eight mature follicles at the time of hCG administration.
  
  
  CONCLUSIONS
  HMC and IUI are effective treatment of some causes of infertility.
authors.affiliation: Division of Reproductive Endocrinology and Infertility, University of Miami School of Medicine, Florida, USA.
authors.forename: B
authors.initials: B
authors.lastname: Vollenhoven
authors.forename: M
authors.initials: M
authors.lastname: Selub
authors.forename: O
authors.initials: O
authors.lastname: Davidson
authors.forename: H
authors.initials: H
authors.lastname: Lefkow
authors.forename: M
authors.initials: M
authors.lastname: Henault
authors.forename: N
authors.initials: N
authors.lastname: Serpa
authors.forename: T T
authors.initials: TT
authors.lastname: Hung
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy; D004967:Estrogens / Q000097:blood; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000628:therapy*; D007315:Insemination, Artificial / Q000379:methods*; D008297:Male; D008596:Menotropins / Q000627:therapeutic use*; D008875:Middle Aged; D016471:Ovarian Hyperstimulation Syndrome / Q000517:prevention & control*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011379:Prognosis; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D004967:Estrogens; D005300:Fertility Agents, Female; D008596:Menotropins